Directed evolution of adeno-associated virus yields enhanced gene delivery vectors

Nature Biotechnology

Volumn 24, Issue 2, 2006, Pages 198-204

  Maheshri, Narendra ^a   Koerber, James T ^a   Kaspar, Brian K ^b   Schaffer, David V ^a  

^a University of California   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELLS; GENE TRANSFER; PROBLEM SOLVING; TISSUE; VECTORS;

ADENO-ASSOCIATED VIRAL VECTORS; GENE DELIVERY VEHICLES; TISSUE TRANSPORT; VECTOR DESIGN;

VIRUSES;

HEPARIN; NEUTRALIZING ANTIBODY;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ARTICLE; CONTROLLED STUDY; EVOLUTION; GENE TARGETING; HIGH THROUGHPUT SCREENING; LIBRARY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; VIRUS CAPSID; WILD TYPE;

ADENOVIRIDAE; DIRECTED MOLECULAR EVOLUTION; DRUG DELIVERY SYSTEMS; GENE TARGETING; GENE THERAPY; GENETIC ENHANCEMENT; GENETIC VECTORS; TRANSFECTION;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 2; ADENOVIRIDAE; MIRIDAE;

EID: 32344438754     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1182     Document Type: Article

References (50)

1. Srivastava, A., Lusby, E.W. & Berns, K.I. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 555-564 (1983).
2. Chiorini, J.A., Kim, F., Yang, L. & Kotin, R.M. Cloning and characterization of adenoassociated virus type 5. J. Virol. 73, 1309-1319 (1999).
3. Davidson, B.L. et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 97, 3428-3432 (2000).
4. Gao, G.P. et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 11854-11859 (2002).
5. Gao, G. et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. USA 100, 6081-6086 (2003).
6. Kay, M.A. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257-261 (2000).
7. Manno, C.S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972 (2003).
8. Moss, R.B. et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125, 509-521 (2004).
9. Samulski, R.J., Chang, L.S. & Shenk, T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63, 3822-3828 (1989).
10. Berns, K.I. & Linden, R.M. The cryptic life style of adeno-associated virus. Bioessays 17, 237-245 (1995).
11. Xiao, X., Li, J. & Samulski, R.J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098-8108 (1996).
12. Halbert, C.L., Rutledge, E.A., Allen, J.M., Russell, D.W. & Miller, A.D. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524-1532 (2000).
13. Koeberl, D.D., Alexander, I.E., Halbert, C.L., Russell, D.W. & Miller, A.D. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc. Natl. Acad. Sci. USA 94, 1426-1431 (1997).
14. Snyder, R.O. et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16, 270-276 (1997).
15. McCown, T.J., Xiao, X., Li, J., Breese, G.R. & Samulski, R.J. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713, 99-107 (1996).
16. Lai, K., Kaspar, B.K., Gage, F.H. & Schaffer, D.V. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat. Neurosci. 6, 21-27 (2003).
17. Erles, K., Sebokova, P. & Schlehofer, J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59, 406-411 (1999).
18. Moskalenko, M. et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74, 1761-1766 (2000).
19. Wobus, C.E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281-9293 (2000).
20. Sun, J.Y., Anand-Jawa, V., Chatterjee, S. & Wong, K.K. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 10, 964-976 (2003).
21. Peden, C.S., Burger, C., Muzyczka, N. & Mandel, R.J. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAVS-mediated, gene transfer in the brain. J. Virol. 78, 6344-6359 (2004).
22. Nguyen, J.B., Sanchez-Pernaute, R., Cunningham, J. & Bankiewicz, K.S. Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12, 1961-1964 (2001).
23. Smith-Arica, J.R. et al. Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors. Cloning Stem Cells 5, 51-62 (2003).
24. Hughes, S.M., Moussavi-Harami, F., Sauter, S.L. & Davidson, B.L. Viral-mediated gene transfer to mouse primary neural progenitor cells. Mol. Ther. 5, 16-24 (2002).
25. Dong, J.Y., Fan, P.D. & Frizzell, R.A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101-2112 (1996).
26. Hermonat, P.L., Labow, M.A., Wright, R., Berns, K.I. & Muzyczka, N. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J. Virol. 51, 329-339 (1984).
27. Rabinowitz, J.E., Xiao, W. & Samulski, R.J. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265, 274-285 (1999).
28. Girod, A. et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med. [published erratum appears in Nat. Med. 1999 Dec;5(12):1438] 5, 1052-1056 (1999).
29. Shi, W., Arnold, G.S. & Bartlett, J.S. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697-1711 (2001).
30. Müller, O.J. et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040-1046 (2003).
31. Perabo, L. et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol. Ther. 8, 151-157 (2003).
32. Opie, S.R., Warrington, Jr., K.H., Jr., Agbandje-McKenna, M, Zolotukhin, S. & Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995-7006 (2003).
33. Walters, R.W. et al. Structure of adeno-associated virus serotype 5. J. Virol. 78, 3361-3371 (2004).
34. Xie, Q. et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405-10410 (2002).
35. Stemmer, W.P. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370, 389-391 (1994).
36. May, O., Nguyen, P.T. & Arnold, F.H. Inverting enantioselectivity by directed evolution of hydantoinase for improved production of I-methionine. Nat. Biotechnol. 18, 317-320 (2000).
37. Boder, E.T. & Wittrup, K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553-557 (1997).
38. Daugherty, P.S., Chen, G., Iverson, B.L. & Georgiou, G. Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc. Natl. Acad. Sci. USA 97, 2029-2034 (2000).
39. Soong, N.W. et al. Molecular breeding of viruses. Nat. Genet. 25, 436-439 (2000).
40. Zhao, H., Giver, L., Shao, Z., Affholter, J.A. & Arnold, F.H. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat. Biotechnol. 16, 258-261 (1998).
41. Zolotukhin, S. et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985 (1999).
42. Rabinowitz, J.E. et al. Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity. J. Virol. 76, 791-801 (2002).
43. Summerford, C. & Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445 (1998).
44. Huttner, N.A. et al. Genetic modification of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizating effects of human serum antibodies. Gene Ther. 10, 2139-2147 (2003).
45. Gao, G. et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388 (2004).
46. Hewat, E. & Blaas, D. in Antibodies in Viral Infections, vol. 260 (ed. Burton, D.R.) 29-44, (Springer-Verlag, Berlin, 2001).
47. Hansen, J., Qing, K., Kwon, H.J., Mah, C. & Srivastava, A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74, 992-996 (2000).
48. Walters, R.W. et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276, 20610-20616 (2001).
49. Batard, P., Jordan, M. & Wurm, F. Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection. Gene 270, 61-68 (2001).
50. Kern, A. et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072-11081 (2003).